logo
Select company
Select metric
15.2%Cash to Assets Ratio
VS
Market
68
Sector
35
Industry
22
History
27
$ 9.84Close
$ 8.24 - $ 28.14 52-Week Range
Ticker Information

Ticker

NRIX

Company Name

NURIX THERAPEUTICS INC

Sector

Healthcare

Industry

Biotechnology

Exchange

NASDAQ

NURIX THERAPEUTICS INC - Cash to Assets Ratio Chart Analysis (TTM)

From
Zoom
1Y
3Y
5Y
10Y

NRIX - Cash to Assets Historical data
DateTotal AssetsCash and EquivalentsCash to Assets Ratio
9/30/2025$ 522.47M$ 79.41M15.2%
6/30/2025$ 591.55M$ 85.16M14.4%
3/31/2025$ 615.04M$ 76.82M12.49%
12/31/2024$ 669.34M$ 110.9M16.57%
9/30/2024$ 513.6M$ 99.94M19.46%
6/30/2024$ 511.03M$ 117.69M23.03%
3/31/2024$ 312.67M$ 50.71M16.22%
12/31/2023$ 355.6M$ 55.53M15.62%
9/30/2023$ 308.19M$ 43.2M14.02%
6/30/2023$ 350.62M$ 59.86M17.07%
Previous (option currently disabled)
1 (current)
Next (option currently disabled)

Key Performance Insights, Last 5 Years

  • NURIX THERAPEUTICS INC's latest trailing twelve months (TTM) Cash to Assets stands at 30.16%.
  • Over the past 5 years, NURIX THERAPEUTICS INC's average Cash to Assets has been 18.7%.
  • The median Cash to Assets for NURIX THERAPEUTICS INC during this period was 16.39%
  • NURIX THERAPEUTICS INC reached its highest Cash to Assets over the past 5 years at 36.37%.
  • The lowest Cash to Assets recorded by NURIX THERAPEUTICS INC in the same timeframe 9.31%

NURIX THERAPEUTICS INC's Cash to Assets vs. competitors

We picked the following companies as peers based on multiple factors, including sector, industry, market capitalization and revenue

Cash to Assets Benchmarks
CompanyCash to Assets
SNDX : SYNDAX PHARMACEUTICALS INC 18.26%URGN : UROGEN PHARMA LTD 45.03%TBPH : THERAVANCE BIOPHARMA INC 66.37%KURA : KURA ONCOLOGY INC 12.01%GYRE : GYRE THERAPEUTICS INC 23.91%ZVRA : ZEVRA THERAPEUTICS INC 18.62%CRMD : CORMEDIX INC 63.07%NAGE : NIAGEN BIOSCIENCE INC 66.07%SAGE : SAGE THERAPEUTICS INC 16.3%EYPT : EYEPOINT PHARMACEUTICALS INC 23.67%

Definition of Cash to Assets Ratio

[Calculation] The Cash to Assets Ratio expresses a company’s cash and cash equivalents [CashnEq] as a percentage of total [Assets].
CashnEq / Assets
(=) Cash to Assets
Cash to Assets for NURIX THERAPEUTICS INC is calculated as follows: CashnEq [ $ 119.53M ] / Assets [ $ 396.34M ]
(=) Cash to Assets [ 30.16% ]

NRIX - Cash to Assets Ratio, Last 5 years

9.31%

Minimum

Mar 31, 2023

36.37%

Maximum

Jun 30, 2021

18.7%

Average

16.39%

Median

Cash to Assets Benchmark Analysis

The chart above depicts the distribution of Cash to Assets for companies in the Total Stock Market. The average Cash to Assets of the companies is 9.84% with a standard deviation of 9.62%.
The following table provides additional summary stats:
Cash to Assets in the Market:
filtered constituents3.95K
min0%
max40.92%
average9.84%
median6.44%
std9.62%